Fig. 3: Challenges facing the current practices of TDE inhibition and clearance with respective recommended solutions to each challenge.
From: Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control
Off-target toxicity is the major challenge reported in all methods used to target TDE and the development of a tumor-targeting delivery tool is suggested as a solution. The development of clinically available pharmacological inhibitor-based tumor therapies will be promoted by combining high-throughput drug screening strategies and targeted drug delivery systems. The trauma and risk of infection, bleeding, and removal of normal exosomes associated with extracorporeal TDE clearance can be avoided with the development of targeted immune-based clearance. This figure has been reproduced from Li et al. 95, with permission from Experimental & Molecular Medicine.
